The results from the MAD trial in healthy volunteers of the on-going Phase I/II clinical trial of a new nebulised formulation of RPL554 are extremely encouraging and highlight the significant potential of RPL554. We believe Verona Pharma is in a strong position to create value through the development of RPL554 for the treatment of COPD and asthma. It has demonstrated a very attractive profile, including synergistic effects with current standard therapy, with its combined bronchodilator and anti- ....
